Matching placebo control

DRUG2 trials

Sponsors

Basilea Pharmaceutica, Retension Pharmaceuticals. Inc.

Conditions

Fungal InfectionUncontrolled Hypertension

Phase 1

Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally

CompletedNCT02957929

Basilea PharmaceuticaFungal Infection

Start: 2016-10-31End: 2017-04-20Updated: 2025-09-10

Phase 2

A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension

RecruitingNCT07142356

Retension Pharmaceuticals. Inc.Uncontrolled Hypertension

Start: 2025-10-31End: 2027-06-01Target: 280Updated: 2026-09-10

Related Papers

Phase 1 drug-drug interaction study to assess the effect of CYP3A4 inhibition and pan-CYP induction on the pharmacokinetics and safety of fosmanogepix in healthy participants

Antimicrobial Agents and Chemotherapy2024-05-175 citations